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ABSTRACT 
 
Brains affected by Alzheimer’s disease (AD) show a large spectrum of mitochondrial 
alterations at both morphological and genetic level. The causal link between amyloid beta 
peptides (Ab) and mitochondrial dysfunction has been established in cellular models of AD 
using Ab concentrations capable of triggering massive neuronal death. However, 
mitochondrial changes related to sublethal exposure to Ab are less known. Here we show that 
subtoxic, 1 mMAb1–42 exposure does not change the mitochondrial shape of living cells, as 
visualized upon the uptake of the non-potentiometric fluorescent probe Mitotracker Green and 
enhanced yellow fluorescent protein (EYFP)-tagged cytochrome c oxidase expression. 
Immunolocalization of oxidative adducts 8-hydroxy-2’-deoxyguanosine, 8-hydroxyguanine 
and 8-hydroxyguanosine demonstrates that one-micromolar concentration of Ab1–42 is also 
not sufficient to elicit dramatic qualitative changes in the RNA/DNA oxidative products. 
However, in comparison with controls, semi-quantitative analysis of the overall mitochondrial 
mass by integrated fluorescence intensity reveals an ongoing down-regulation in 
mitochondrial biosynthesis or, conversely, an enhanced autophagic demise of Ab treated cells. 
Furthermore, a significant increase of the full-length mitochondrial DNA (mtDNA) from Ab-
treated versus control cells is found, as measured by long range polymerase chain reaction 
(PCR). Such up-regulation is accompanied by extensive fragmentation of the unamplified 
mtDNA, probably due to the detrimental effect of Ab. We interpret these results as a sequence 
of compensatory responses induced by mtDNA damage, which are devoted to repression of 
oxidative burst. In conclusion, our findings suggest that early therapeutic interventions aimed 
at prevention of mitochondrial oxidative damage may delay AD progression and help in 
treating AD patients. 
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Introduction 
 
Alzheimer’s disease (AD) is a late-onset, progressive, age-dependent neurodegenerative 
disorder whose biological hallmarks reside in the progressive formation of amyloid plaques 
and neurofibrillary tangles1,2, ultimately leading to synaptic failure, disconnection syndrome 
and neuronal cell death, which are clinically manifested by the impairment of cognitive 
functions and changes in behavior and personality3. Advancements in molecular, cellular and 
animal models of AD, as well as post-mortem examination of brain neurons from AD 
patients, have revealed that the formation of beta-amyloid (Ab) peptides and their entrance 
into mitochondria are the prominent factors in cellular changes in the AD brain because they 
induce the generation of free radicals and oxidative damage in AD brain4,5. Since neuronal 
viability is highly dependent on oxidative energy metabolism6, the impaired mitochondrial 
functions are having an enormous influence on AD manifestation and progression. Beta-
amyloid peptides increase the intracellular generation of reactive oxygen species (ROS), 
particularly hydrogen peroxide (H2O2), thus making mitochondria both targets and sources of 
oxidative stress7,8. In turn, oxygen derived molecules give rise to oxidative adducts, such as 8-
hydroxy-2’-deoxiguanosine (8OHdG)9,10, as a part of mitochondrial DNA (mtDNA) isolated 
from AD brains. Higher levels of OHdG have been found at the initial stages of AD in 
postmortem brain sections by means of immunocytochemistry and the detection of oxidized 
nucleic acids was shown to be reduced with disease progression11,12. The pioneering paper by 
Suter and Richter13 identified that fragmented mtDNA is the predominant carrier of oxidized 
DNA bases and presence of 8OHdG. Other studies addressing prominent features of 
vulnerable neurons in AD have revealed a significant reduction of cytoplasmic area covered 
by intact mitochondria, which is balanced by up-regulating both average size and total 
mitochondrial DNA (mtDNA) in individual cells14. Moreover, as revealed by in situ 
hybridization and immunocytochemistry in the very same brain section, the overlap in 
localization of mtDNA D5kb and 8OHdG seemed to support an intimate relationship between 
neuronal oxidative damage and dysmorphic mitochondria. In contrast, in most AD cases 
examined by de la Monte and collaborators15 the mean level of mtDNA was found to be 
significantly lower than in the control group. These data have been corroborated by the 
findings that in AD cells mtDNA content was higher in cybrids that harbor low to medium 
levels of 4977 bp-deleted mtDNA16. In addition, oxidative stress induced by sublethal 
concentrations of hydrogen peroxyde has been found to cause an increase in mtDNA content 
that correlates with a larger amount of functional mitochondria17,18. The quantitative relevance 
of toxic inducers has been recently confirmed by the ability of micromolar concentrations of 
hydrogen peroxide to provoke true oxidative lesion of genomic DNA19. However, 
experimental data on mtDNA is still missing. Interestingly, while neurodegeneration can be 
observed with very low doses of Ab, a dramatic viability drop in non-primary neuronal 
cultures is induced only by concentrations greater than 10 mM of Ab1–40, thus allowing the 
definition of a threshold for the so-called subtoxic level of Ab20. 
   Our current investigation was aimed to: 1) assess whether sublethal doses of Ab1–42 could 
provoke specific alterations to mitochondria both with regard to morphological and 
quantitative features and DNA content, 2) determine if genetic and structural changes occur 
concomitantly, and 3) verify if DNA oxidation at mitochondrial or nuclear level can be 
triggered by low doses of Ab1–42. 
 
Materials and Methods 
 
Cell cultures 
 
Neuroblastoma cell lines (clone SH-SY5Y) were grown in Minimal Essential Medium 
(MEM) containing Earle’s salt supplemented with 10% heat inactivated fetal bovine serum 
(FBS), 2 mM L-glutamine, 1% non-essential amino acids, streptomycin (100 
mg/mL)/penicillin (100 U/mL) (all reagents from Invitrogen, Gaithersburg, MD, USA) and 
maintained at 37°C in a humid atmosphere with 5% CO2. One week after seeding when cells 
reached about 80% confluence, they were exposed to Ab1–42 peptide acetate or chloride salt 
(Recombinant Peptide Technologies, Athens, OH, USA) dissolved in ultra-pure water and 
previously incubated for 4 days at 37°C (in order to ensure formation of fibrils necessary for 
toxic induction). Finally, cells were treated for 24 hr with 1 mM Ab1–42 in complete medium 
without FBS. 
 
Gene transfection 
 
Enhanced yellow fluorescent protein (EYFP)-tagged cytochrome c oxidase subunit IV gene 
has been used to target mitochondrial matrix21,22. SH-SY5Y cells were stably transfected with 
Lipofectamine 2000 (Invitrogen) by selection with the antibiotic G418 (Invitrogen) and then 
exposed to Ab1–42 as referred above. 
 
Mitochondria labeling 
 
After 24-hr Ab1–42 exposure, neural cells were washed twice with PBS and supravitally 
stained with 400 nM Mitotracker Green fluorescent marker (Molecular Probes, Eugene, OR, 
USA) diluted from 1 mM DMSO stock solution. Cells were washed with medium and 
observed using a Zeiss Axioskop microscope (Zeiss, Oberkocken, Germany) equipped with 
differential interference contrast optics, planachromatic objective lenses (40x/0.75 Na water 
immersion) and standard filters adapted for Mitotracker (460–500 BP excitation, 505 splitter, 
510–560 BP emission). Grayscale images were acquired by a 8-bit cooled CCD camera 
(Sensicam, PCO Computer Optics, Kehlheim, Germany) with a 1280x1024 pixel chip. Image 
analysis was performed using the Image-Pro Plus software (Media Cybernetics, Silver Spring, 
MD, USA). 
 
Immunocytochemistry 
 
A monoclonal mouse antibody against oxidative adducts 8-hydroxy-2’-deoxyguanosine, 8-
hydroxyguanine, and 8-hydroxyguanosine (anti-8OHdG) was used as a marker of DNA (both 
genomic and mitochondrial) and RNA oxidative damage (Autogen Bioclear, Calne, UK). 
Neuroblastoma cells were fixed in periodate-lysine-paraformaldehyde (PLP) for 15 min at 
37°C. After rinsing with PBS containing 0.2% Triton X-100, 10% normal goat serum (NGS) 
(Vector Laboratories Inc., Burlingame, CA, USA) was applied for 1 hr at room temperature 
(RT). Then, anti-OHdG antibody (5 mg/mL) diluted in PBS containing 0.3% Triton X-100 
and 2% NGS was added for 24 hr at RT. After an extensive washing with PBS, samples were 
incubated for 40 min at RT with fluorescein (FITC) conjugated anti-mouse antibody (Jackson 
Immunoresearch Labs, West Grove, PA, USA), and rinsed with PBS. Nuclear morphology 
was evaluated by DAPI staining (5 mg/mL; Molecular Probes, Eugene, OR, USA) for 5 min 
at RT. Cell imaging and analysis were performed as described above. 
 
DNA extraction 
 
Cells were scraped, centrifuged at 500x g for 10 min and resuspended in extraction buffer 
composed of 10mM Tris-HCl (pH 8), 100 mM EDTA (pH 8), 20 mg/mL RNAse, 0.5% SDS 
and 0.1 mg/ml proteinase K. The samples were then gently shaked for 18 hr at RT. DNA 
extraction was carried out at 4°C according to Blin and Stafford23, with some modifications. 
First, an equal volume of phenol/ chloroform/isoamyl alcohol 25/24/1 mixture was added. 
Upon centrifugation (1500x g, 10 min), the aqueous phase was transferred to a new tube with 
an equal amount of chlorophorm/isoamyl alcohol 24/1 and then centrifuged again. DNA was 
precipitated by adding 0.3M sodium acetate, pH 5.2 (1 volume), 100% cold ethanol (2 
volume), then air dried and immediately dissolved in ultra-pure water. 
 
Long extension Polymerase Chain Reaction (LX-PCR) 
 
Long extension PCR for amplification of the entire mitochondrial genome was carried out 
using outwards primers located in the cytochrome b gene8 that correspond to the following 
sequences: 
5’-TGAGGCCAAATATCATTCTGAGGGGC-3’ 
(forward primer, 15148-15174 bp) and 
5’-TTTCATCATGCGGAGATGTTGGATGG-3’ 
(reverse primer, 14841-14816 bp), to generate a 16231 bp molecule. 
The reaction components (25 mL) consisted of 0.5 mM dNTPs (Pharmacia, Uppsala, 
Sweden), 0.3 mM primers (MWG-Biotech, Firenze, Italy), 100 ng genomic DNA as a bottom 
phase. This master mix was overlaid with 25 mL of 1x buffer and 2.5 Us enzyme mixture 
(Expand long template PCR system, Roche Diagnostics GmbH, Mannheim, Germany). 
Thermo-cycling profile involved the following steps: 1) initial denaturation (92°C, 2 min), 2) 
denaturation (92°C, 10 sec), annealing (70°C, 30 sec), extension (68 °C, 12 min), for a total of 
10 cycles, 3) denaturation (92°C, 10 sec), annealing (70°C, 30 sec) with increasing annealing 
time by 20 sec increments in each successive cycle, extension (68°C, 12 min), for a total of 20 
cycles, and 4) final extension (68°C, 7 min). PCR products were loaded onto a 0.4% MP 
agarose gel (Roche Diagnostics GmbH, Mannheim, Germany) in 1x Tris-Acetate-EDTA 
(TAE) at 25 V for 18 h. Finally, gel was stained with Sybr Green (Molecular Probes, Eugene, 
OR, USA) according to the manufacturer instructions. 
   In order to avoid possible quantitative differences due to methodological reasons several 
DNA purified samples were amplified and run on the same gel in the same electrophoresis 
chamber. 
 
Determination of mitochondrial mass and statistics 
 
All of the experiments have been repeated at least three times. Mitochondrial mass was 
evaluated by measuring the integrated fluorescence intensity of mitochondrial profiles stained 
by Mitotracker dye under assumption that dye is insensitive to differences in potential. Due to 
the considerable skewness of distributions, data comparisons were made using the non-
parametric test of Kruskal-Wallis with a significance level of p<0.05. 
 
Results 
 
Although Ab-treated cells were having higher levels of oxidative damage (see below), both 
control (Figure 1a) and Ab-treated cells (Figure 1b) showed bright immunofluorescence for 
8OhdG and appeared relatively similar. As to the cytological distribution of oxidative 
adducts, again in both Ab-treated and control cells 8OHdG was mainly concentrated in the 
cytoplasmic domain with peaks of fluorescence in the perinuclear area, whereas nuclei 
showed a very weak immunolabeling. In addition, the largest cells displayed a granular 
immunolocalization regardless of Ab exposure, probably as a consequence of the segregation 
of oxidative DNA/RNA adducts within organelles (e.g. ribosomes and mitochondria). 
Fluorescent traces were also present along the emergence of neuronal processes that soon 
disappeared at longer distance. 
   Morphological analysis was based on mitochondrial staining by Mitotracker uptake and 
EYFP cytochrome c oxidase transfected cells. Mitochondria of control cells labeled with 
Mitotracker were highly fluorescent. Fluorescence was distributed throughout the cytoplasm 
apparently in conjunction with a reticular organization of filamentous profiles (Figure 2a). 
However, despite the continuity of mitochondrial network, Mitotracker load was often 
variable from cell to cell. Due to the inherent properties of Mitotracker used, this phenomenon 
could not be ascribed to fluctuations of mitochondrial potential. Uneven distribution of the 
dye was quite similar to the one observed in mitochondria of Ab treated samples (Figure 2b). 
We therefore measured the integrated area of several fluorescent mitochondria. In comparison 
to controls (7664, 9275.9, 8036.2), we found a significant decrease in median values of the 
randomly selected and examined Ab samples (7368.7, 4812.6, 7462.55, respectively). 
Alterations of mitochondrial network were absent in Ab exposed cells, as confirmed by 
incubation with an excess of phosphate salts that triggered a robust swelling accompanied by 
extensive fragmentation of mitochondria (Figure 2c). 
   By means of transfection, in neuronal cells containing mitochondria tagged with EYFP, the 
import of the cytochrome oxidase subunit IV into the mitochondrial matrix resulted in a 
specific mitochondrial morphology. Our data showed a fluorescent pattern overlapping with 
Mitotracker stained mitochondria (Figure 3a). In addition, mitochondria filaments extended 
their localization to neuritic processes. The exposure to 1mMAb seemed to be ineffective at 
inducing mitochondria to become fragmented or swollen (Figure 3b). Observed enlargements 
could be occasionally distinguished along mitochondrial strings, but were independent to the 
Ab treatment. 
   Results of LX-PCR experiments showed the single distinct band corresponding to ~16.3 kb 
of the entire mitochondrial human genome (Figure 4). Interestingly, the sharp band (16.3 kb) 
obtained with the two Ab samples was roughly double in thickness compared to the 
correspondent mtDNA of control cells. In addition, PCR products from Ab treated cells 
consisted of a smear of fragments with higher and lower average length plus two more 
fragments with very low molecular weight. Such findings were not replicated with amplified 
DNA from control cells. Moreover, electrophoresis of mtDNA showed a higher background 
which was representative of random DNA fragmentation when the neuroblastoma cells had 
been cultured in presence of the toxic peptides. 
 
Discussion 
 
During last several years the relationship between mitochondria dysfunctions and Ab 
accumulation have gained increasing interest due to pivotal role of mitochondria in the AD 
neurodegenerative process25–27.Within this framework, one of the major issues is an 
unpredictable time window between Ab driven plaque formation and the occurrence of 
clinical symptoms of AD. In search of initial signals affectingmitochondrial architecture and 
mtDNA content, we designed an experimental model where low dose exposure to Ab1–42 was 
well below the threshold for inducing immediate cell death, but still high enough for the 
induction of subtle cellular changes. 
   The main finding of this study is that total mtDNA content was up-regulated in Ab treated 
cells compared to control cells, as revealed by LX-PCR. The extensive increase of mtDNA 
was also accompanied by a higher degree of fragmentation, as visualized by a more evident 
smear of DNA and thicker bands of DNA with low molecular weights. These findings 
indicate that DNA synthesis may occur concomitantly with a diffuse degradation of 
mitochondrial genome. This is consistent with previous reports where the increase of mtDNA 
and mitochondria has been interpreted as one of the molecular events gearing the cells up to 
cope with mild to medium stress17,18. However, when cells are overwhelmed by high 
oxidative stress, due to the impaired replication of mtDNA and biogenesis of mitochondria, 
such a physiological switch may be no longer be effective. 
   A measurement of total mtDNA in a pure population of neuronal cells has not been 
extensively studied. The only two papers14,15 that have systematically addressed the variability 
of mtDNA content in postmortem AD brains ended up with conclusions that are difficult to 
resolve. The first group reported a reduction of mtDNA in AD that positively correlated with 
an increase in mtDNA fragmentation, but was »paradoxically« linked to the increase of 
mitochondrial mass14. On the other hand, although total mtDNA in AD was increased in 
several neuronal populations, much of this mtDNA was present in digestive organelles and 
therefore potentially unsuitable for extraction and amplification, as observed by the other 
group15. Due to the reduced numbers of intact mitochondria the amount of amplifiable 
mtDNA was also reduced15. We think that those divergent and controversial results might be 
explained on the basis of different methodological approaches. Namely, at least some of the 
differences obtained could be attributed to excessive glial cell reaction associated with cell 
loss or proliferation of mitochondria in degenerating neurons, which could also heighten the 
overall mitochondrial genetic content. In our study, we were confident that the specificity of 
the primers within the highly conserved cytochrome b gene made the LX-PCR method 
qualitatively reliable for the amplification of a linear product equivalent to the entire 
mitochondrial genome24, what allows the detection of mutational events such as deletions in 
different tissues28,29, including the human brain30. However, this method has also received a 
lot of criticism as a quantitative assay due to possible technical artifacts (e.g. variations in 
template DNA concentration) that can lead to the misinterpretation of LX-PCR results31. The 
only alternative source of information that may help resolving this puzzle has been offered 
through the analysis of AD brain tissues where much of the increased mtDNA was 
ultrastructurally segregated in autophagocytic compartments and therefore unavailable for 
PCR amplification14. 
   We also tried to verify a positive correlation between the quantitative variation of the 
mitochondrial genomeand possible alterations in terms of mass and shape of the overall 
mitochondria. Measurements of integrated fluorescence area for the evaluation of total 
mitochondrial mass revealed a slight, though statistically significant, decrease of the overall 
content of mitochondria in case of Ab exposure. This finding is consistent with the absence of 
clear morphological alterations of mitochondria such as swelling or fragmentation. Indeed, 
without any de novo mitochondria biosynthesis, only enlargements of mitochondria could 
eventually account for a total increase in the TMRM (tetramethyl rhodamine methyl ester) 
stained fluorescent area. Despite the fact that the morphology and dynamics mitochondria 
have tissue and cell specific features32, in vivo image analysis has shown a direct correlation 
between mitochondrial DNA depletion and disruption of the mitochondrial reticulum, which 
resulted in formation of vesicular organelles with circular cristae33. A confirmation of this 
phenomenon has emerged from description of individual mitochondria changing their 
morphology in accordance with mtDNA redistribution and intimate relationship to cell cycle 
phases34. 
   Some previous reports have shown that, in comparison to controls, an approximately 
eightfold increase in morphologically abnormal (swelled or enlarged) mitochondria after six 
passages of cybrid cell lines from sporadic AD subjects35. In contrast to these reports, we have 
demonstrated that up-regulation of the mitochondrial genome does not necessarily imply 
either such a great increase of mitochondrial mass or an impairment of normal morphology. 
This result is relevant since it is supposed that low levels of Ab would have mtDNA as a 
primary target before the appearance of the irreversible damage of mitochondrial filaments. 
At this point it should be clarified that in our model we circumvented possible unspecificity of 
TMRM due to inefficient uptake or the ongoing efflux mediated by MDR pumps upon Ab 
treatment by using EYFP cytochrome c oxidase transfected cells. This method has been 
extensively used to track mitochondria because of the transmembrane distribution of the 
enzyme. Cytochrome c oxidase-tagged mitochondria were also resistant to the toxic effects of 
Ab because the continuity of fluorescence pattern was unchanged even after the amyloid 
insult. This finding confirmed earlier notion that in physiological conditions the reticular form 
better drives rapid transmission of energy through the propagation of a membrane potential 
and therefore facilitates energy delivery from the cell periphery to the cell core36. 
   Finally, since a recent review37 proposed a »chameleon « role for Ab (a phenomenon 
obviously dependent upon Ab concentration which, in turn, determines in vitro fibrillization 
rate), always swinging between the prooxidant and anti-oxidant activities, in this study we 
also investigated if Ab1–42 exposure is per se a biochemical inducer of DNA oxidation. 
Although some previous reports found 8OHdG-immunopositive neurons in AD brain 
sections12, we have found no experimental evidence in neuronal cell culture to support this 
view. Since in our model we observed a steady-state level of 8OHdG immunoreactivity, our 
results are consistent with the antioxidant role of Ab1–42 when applied at concentrations lower 
than 10 mM. These data were also validated by the minimal fraction of cells that were 
committed to cell death (data not shown), and are in accordance with the published 
observations where 5 mM Ab induced only 15% decrease in the viability properties of SY5Y 
cells, as compared to controls38. 
   Recent advances in model studies of AD have revealed that Ab and other amyloid precursor 
protein (APP) derivatives (particularly mutated ones) are key factors which enter into 
mitochondria and induce the generation of free radicals and oxidative damage in AD 
neurons5. Evidence from biochemical and gene expression studies has also suggested that 
mitochondrial abnormalities per se are critical for the initiation of late-onset sporadic AD4. 
However, the precise causal links between mitochondrial abnormalities and synaptic damage-
based cognitive decline are still unknown. Since currently approved drugs for AD 
(acetylcholinesterase inhibitors tacrine, galantamine, donepezil and rivastigmine and non-
competitive antagonist of NMDA receptors memantine) provide only temporary relief of 
some symptoms of dementia and do not modify AD pathology, there is an urgent need for 
development of alternative therapeutic strategies. Antioxidants tested so far were found to be 
safe, had few adverse effects, readily crossed blood brain barrier and appear to be a promising 
mitochondrial medicine to improve cognitive functions of AD patients5. In this context, the 
results reported here may serve as a starting point for development of more sophisticated 
models of beta amyloid toxicity in which the action of anti-oxidative compounds could be 
tested. On the other side, it would be of particular relevance to test how modulation of metal 
ions (such as copper, zinc and iron) reduction affect mitochondrial DNA oxidation in the 
presence of minimal amounts of fibrillogenic Ab. 
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Legends 
 
 
Fig. 1. Distribution of anti-8OHdG immunofluorescence. a: Under basal conditions, 8OHdG-
like immunolabeling is strongly detected in the cytoplasmic domain while nuclei reveal very 
low immunoreactivity. Notably, the largest cells contain a granular fluorescent signal spread 
over the abundant cytoplasm. Some neurites are also stained by the anti-8OHdG antibody. b: 
Cells exposed to Ab1–42 are also immunopositive regardless to the cell size. Scale bar = 10 
µM 
 
 
Fig. 2. Mitochondria distribution and shape upon Mitotracker uptake. a: Control cells display 
a reticular organization of mitochondria filling the whole cytoplasm, but rarely reaching the 
neuritic processes. The highest peaks of fluorescence are obtained possibly due to overlapping 
of mitochondrial elements. b: In Ab1-42 treated cells, the overall architecture of mitochondria 
was unaltered as compared to control cells, albeit with the additional feature of isolated cells 
being more sensitive to photobleaching. c: Incubation of neuroblastoma cells in hypotonic 
solution affects the continuity and size of fluorescent mitochondria. As a result, fragmented 
and swollen structures can be observed. Scale bar = 10 µM. 
 
 
 Fig. 3. EYFP-tagged cytochrome c oxidase protein expression in living cells. a: The 
distribution pattern in control cells is consistent with the specific accumulation within the 
mitochondria. Mitochondria are represented by a mesh of filaments sometimes detectable 
in the shape of single string. b: Ab1–42 has no effect on EYFP labeled mitochondria. The 
fluorescent dots could be occassionally detected, probably due to the initial storage of the 
cytochrome c oxidase. Scale bar = 10 µM. 
 
 
Fig. 4. SYBR Green stained gel of LX-PCR using DNAs from two different experiments (see 
text for explanation). Specific bands representative of the entire mitochondrial genome (16.3 
Kb) exhibited the strongest signal in the Ab1–42 samples. A smear of fragments above or 
below 16.3 Kb was more enhanced in the presence of Ab1–42. The additional band between 
10 and 8.6 Kb was more evident in DNAs of treated cells. Duplicate experiments of control 
and Ab1–42 DNAs were indicated as C1, C2 and Ab1, Ab2 respectively. 
 
 
MORFOLOGIJA I STANJE DNA MITOHONDRIJA NAKON SUBLETALNE 
EKSPOZICIJE PEPTIDOM BETA-AMILOIDA1–42 
 
SAŽETAK 
 
U mozgova osoba s Alzheimerovom bolešću (AD) vidi se veliki spektar mitohondrijalnih 
promjena kako na morfološkoj, tako i na genetskoj razini. U staničnim modelima AD 
pronađena je kauzalna povezanost između prisutnosti peptida beta-amiloida (Ab) i disfunkcije 
mitohondrija samo uz upotrebu koncentracija Ab koje su sposobne izazvati masivnu smrt 
neurona. No, mitohondrijalne promjene povezane sa subletalnom ekspozicijom Ab nisu tako 
dobro proučene. U ovom smo istraživanju pokazali da subtoksična ekspozicija s 1 mM Ab1–42 
ne mijenja oblik mitohondrija stanica u kulturi, što je jasno vidljivo nakon vizualizacije 
mitohondrija pomoću na razlike u potencijalu neosjetljive fluorescentne probe Mitotracker 
Green i na temelju ekspresije citokrom c oksidaze označene modificiranim žutim 
fluorescentnim proteinom s poboljšanom emisijom (EYFP). Imunolokalizacija oksidativnih 
kompleksa 8-hidroksi-2’-deoksigvanozina, 8-hidroksigvanina i 8-hidroksigvanozina pokazala 
je da jednomolarna koncentracija Ab1–42 također nije dovoljna da bi izazvala dramatične 
kvalitativne promjene vizualiziranih oksidativnih produkata RNA i/ili DNA. Ipak, u 
usporedbi s kontrolama, semikvantitativnom analizom mitohondrijalne mase izmjerene iz 
intenziteta ukupne fluorescencije otkrili smo značajne razlike koje ukazuju da dolazi ili do 
sveukupnog smanjivanja biosinteze mitohondrija ili pak da se radi o pojačanoj autofagičkoj 
eliminaciji stanica tretiranih s Ab. Nadalje, upotrebom lančane reakcije polimeraze dugog 
odsječka (long range PCR) u stanica tretiranih s Ab pronašli smo značajan porast cijele 
mitohondrijalne DNA (mtDNA). Ovakva pojačana sinteze cijele mtDNA bila je popraćena 
izraženom fragmentacijom neamplificirane mtDNA, vjerojatno uslijed štetnog djelovanja Ab. 
Dobivene rezultate interpretirali smo kao niz kompenzatornih procesa izazvanih 
oštećenjem mtDNA, kojima je cilj zaustavljanje naglog porasta oksidacije. Zaključno, naši 
nalazi ukazuju da bi rane terapijske intervencije usmjerene na prevenciju oksidativnog 
oštećenja mitohondrija mogle odgoditi progresiju AD i pomoći u liječenju bolesnika s AD. 
 
